Instruction for use: Vaccinum parotitidi-morbillorum culturarum vivum siccum

Dosage form: Lyophilizate for the preparation of a suspension

Active substance: Vaccinum ad prophylaxim morbillorum, parotitidis

ATX

J07BD51 Measles virus in combination with mumps virus, live attenuated

Pharmacological group

Vaccines, serums, phages and toxoids

Nosological classification (ICD-10)

B05 Measles: Koplik Spots; Koryvyaya rash on the mucous cheek

B26 Epidemic parotitis: Parotitis; Infectious parotitis (mumps)

Z27.8 The need for immunization against other combinations of infectious diseases

Composition and release form

1 dose of lyophilized powder for the preparation of solution for SC administration contains measles virus not less than 1000 TCD50, mumps virus not less than 20,000 TCD50 and gentamycin sulfate not more than 25 mkg; In ampoules of 1 dose, in a cardboard pack of 10 ampoules.

Characteristic

Homogeneous porous mass of pink color, hygroscopic.

Pharmachologic effect

Mode of action - Immunostimulating.

It stimulates the production of antibodies to measles and mumps viruses, reaching a maximum level 3-4 weeks and 6-7 weeks after vaccination, respectively.

Indications of the Vaccinum parotitidi-morbillorum culturarum vivum siccum

Scheduled and emergency prevention of measles and mumps.

Contraindications

Hypersensitivity (including aminoglycosides, quail egg protein), a pronounced reaction or complication to the previous dose, primary immunodeficiency states, malignant blood diseases, neoplasms, pregnancy.

Application of pregnancy and breastfeeding

Contraindicated in pregnancy.

Dosing and Administration

SC, immediately before use, mix the vaccine with the solvent (0.5 ml of solvent for 1 vaccine dose of vaccine), inject 0.5 ml under the shoulder blade or into the shoulder region (on the border between the lower and middle third of the shoulder, on the outside). Routine vaccinations are carried out twice at the age of 12 months and 6 years for children who do not have measles and mumps epidemic.

Emergency prophylaxis is given to children aged 12 months, adolescents and adults who have contact with sick measles or mumps, who have not been infected with these infections and not vaccinated against them in accordance with the vaccination schedule (the vaccine is administered no later than 72 hours after contact with the patient).

Precautionary measures

Vaccination can be carried out at the end of acute manifestations of infectious and non-infectious diseases, exacerbations of chronic diseases; After the normalization of body temperature with non-severe forms of acute respiratory viral infection or acute intestinal diseases; 3-6 months after immunosuppressive therapy. After the administration of human immunoglobulin preparations, inoculations against measles and mumps are carried out no earlier than 2 months later. After the introduction of mumps-measles vaccines, immunoglobulin preparations are administered no earlier than 2 weeks later. If immunoglobulin is required before this time, vaccination against measles and mumps should be repeated.

Storage conditions of the drug Vaccinum parotitidi-morbillorum culturarum vivum siccum

At a temperature not exceeding 8 ° C. In accordance with JV 3.3.2.028-95.

Keep out of the reach of children.

The shelf life of the drug Vaccinum parotitidi-morbillorum culturarum vivum siccum

1 year.

Do not use beyond the expiration date printed on the package.